Found: 28
Select item for more details and to access through your institution.
Phase I trial of the TNF-α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas.
- Published in:
- Nature Communications, 2022, v. 13, p. 1, doi. 10.1038/s41467-022-33719-6
- By:
- Publication type:
- Article
Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study.
- Published in:
- Japanese Journal of Clinical Oncology, 2021, v. 51, n. 8, p. 1261, doi. 10.1093/jjco/hyab072
- By:
- Publication type:
- Article
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.
- Published in:
- Nature Medicine, 2014, v. 20, n. 9, p. 1027, doi. 10.1038/nm.3667
- By:
- Publication type:
- Article
Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Identifying the Optimal Radiation Dose in Locally Advanced Non-Small-cell Lung Cancer Treated With Definitive Radiotherapy Without Concurrent Chemotherapy.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Regulatory B Cell Function Is Suppressed by Smoking and Obesity in H. pylori-Infected Subjects and Is Correlated with Elevated Risk of Gastric Cancer.
- Published in:
- PLoS ONE, 2015, v. 10, n. 7, p. 1, doi. 10.1371/journal.pone.0134591
- By:
- Publication type:
- Article
Breast adipose tissue‐derived extracellular vesicles from obese women alter tumor cell metabolism.
- Published in:
- EMBO Reports, 2023, v. 24, n. 12, p. 1, doi. 10.15252/embr.202357339
- By:
- Publication type:
- Article
Diagnosis, testing, treatment, and outcomes among patients with advanced non‐small cell lung cancer in the United States.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 24, p. 21605, doi. 10.1002/cam4.6694
- By:
- Publication type:
- Article
Amplification of IFN-a-induced STAT1 activation and inflammatory function by Syk and ITAM-containing adaptors.
- Published in:
- Nature Immunology, 2004, v. 5, n. 11, p. 1181, doi. 10.1038/ni1126
- By:
- Publication type:
- Article
Non-small cell lung carcinomas with diffuse coexpression of TTF1 and p40: clinicopathological and genomic features of 14 rare biphenotypic tumours.
- Published in:
- Histopathology, 2023, v. 82, n. 2, p. 242, doi. 10.1111/his.14801
- By:
- Publication type:
- Article
Non‐small cell lung carcinomas with diffuse coexpression of TTF1 and p40: clinicopathological and genomic features of 14 rare biphenotypic tumours.
- Published in:
- Histopathology, 2023, v. 82, n. 1, p. 242, doi. 10.1111/his.14801
- By:
- Publication type:
- Article
Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 72, n. 2, p. 453, doi. 10.1007/s00280-013-2219-5
- By:
- Publication type:
- Article
A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion.
- Published in:
- 2011
- By:
- Publication type:
- journal article
A phase 2 study of weekly albumin-bound paclitaxel (Abraxane) given as a two-hour infusion.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 68, n. 5, p. 1331, doi. 10.1007/s00280-011-1621-0
- By:
- Publication type:
- Article
A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2010, v. 66, n. 6, p. 1079, doi. 10.1007/s00280-010-1265-5
- By:
- Publication type:
- Article
Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION.
- Published in:
- British Journal of Cancer, 2024, v. 130, n. 10, p. 1679, doi. 10.1038/s41416-024-02615-9
- By:
- Publication type:
- Article
Immune biomarkers and response to checkpoint inhibition of BRAF<sup>V600</sup> and BRAF non-V600 altered lung cancers.
- Published in:
- 2022
- By:
- Publication type:
- journal article
ctDNA Dynamics, Prognostic Markers, and Mechanisms of Resistance in Tepotinib-treated MET exon 14 (METex14) Skipping NSCLC in the VISION Trial.
- Published in:
- Journal of Oncology Navigation & Survivorship, 2023, v. 14, n. 11, p. 352
- By:
- Publication type:
- Article
Intracranial Activity of Tepotinib in Patients with MET Exon 14 (METex14) Skipping Non-- Small-Cell Lung Cancer (NSCLC) Enrolled in VISION.
- Published in:
- Journal of Oncology Navigation & Survivorship, 2022, v. 13, n. 11, p. 376
- By:
- Publication type:
- Article
Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UK.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 2, p. 191, doi. 10.1007/s11523-024-01038-z
- By:
- Publication type:
- Article
Missing the mark in FGFR1-amplified squamous cell cancer of the lung.
- Published in:
- 2016
- By:
- Publication type:
- Editorial
Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.
- Published in:
- Cancer (0008543X), 2013, v. 119, n. 2, p. 356, doi. 10.1002/cncr.27730
- By:
- Publication type:
- Article
Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas.
- Published in:
- Cancer (0008543X), 2012, v. 118, n. 23, p. 5840, doi. 10.1002/cncr.27637
- By:
- Publication type:
- Article
Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib with Other MET Inhibitors for the Treatment of Advanced NSCLC with MET Exon 14 Skipping Mutations.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 7, p. 3159, doi. 10.1007/s12325-022-02163-9
- By:
- Publication type:
- Article
Long‐term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.
- Published in:
- Cancer Science, 2024, v. 115, n. 4, p. 1296, doi. 10.1111/cas.16107
- By:
- Publication type:
- Article
A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-20935-9
- By:
- Publication type:
- Article